INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of a class (the “Class”) comprising all persons or entities who purchased the securities of Retrophin, Inc. (“Retrophin” or the “Company”) (NASDAQ:RTRX) between March 27, 2014 and September 30, 2014, inclusive (the "Class Period"). If you are a shareholder who purchased Retrophin securities during the Class Period, you have until December 19, 2014 to ask the Court to appoint you as Lead Plaintiff for the class.

Please contact Lesley Portnoy or Casey Sadler at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

The complaint against the Company alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, prospects and performance. Specifically, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Retrophin's founder and Chief Executive Officer was trading Company stock in violation of the Company's Incentive Compensation Plan and other securities rules; (ii) these trading irregularities included grants of shares in violation of the Company's Incentive Compensation Plan and the failure to disclose stock grants to employees; and (iii) as a result of the above, the Company's statements were materially false and misleading at all relevant times.

On September 16, 2014, after the close of trading, the Company issued a press release and filed a Form 8-K with the SEC announcing that on September 15, 2014, it had reached an agreement with its Chief Financial Officer, Marc Panoff, pursuant to which Mr. Panoff's employment with the Company will terminate, effective as of February 28, 2015. Also, the Company announced that on September 10, 2014, Jeffrey Paley, MD abruptly stepped down as a member of the Board of Directors. As a result of this news, shares of Retrophin fell $1.03 or over 8%, on unusually heavy trading, to close at $11.46 on September 17, 2014.

Furthermore, on September 30, 2014, after the close of trading, the Company issued a press release announcing that its Board of Directors terminated its Chief Executive Officer, Martin Shkreli, effective immediately, and appointed Stephen Aselage as interim Chief Executive Officer. As a result of this news, shares of Retrophin fell $0.40 or almost 4.5%, on unusually heavy trading, to close at $8.62 on October 1, 2014.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.